CURATIS HOLDING AG SF-,10
CURATIS HOLDING AG SF-,10/ CH1330780979 /
KNRS/Z
- -
|
Chg.
-
|
Volume |
Bid- |
Ask- |
High |
Low |
-EUR
|
-
|
0 Turnover: 0.00 |
-Bid Size: - |
-Ask Size: - |
- |
- |
Business description
Curatis acquires, licenses, distributes, and promotes medicines for the treatment and/or prevention of orphan and specialty diseases in Switzerland that have been developed and brought to market by third party pharmaceutical companies. Curatis has exclusive distribution rights for more than 30 different drugs in Switzerland – many of them orphan disease and specialty disease medicines. This underlines Curatis' position in the Swiss orphan drug market.
Curatis has set the goal of significantly increasing the number of third-party drugs under contract in Switzerland. In addition, Curatis aims to secure distribution rights for drugs in major European markets such as Germany, France, the UK, and Italy, reflecting a clear vision for growth and market expansion. In the medium to long term, Curatis expects to launch its own products if its development projects gain regulatory approval. Curatis expects this expansion strategy to be supported by the increased visibility and funding opportunities associated with becoming a part of a publicly listed group.
Management board & Supervisory board
CEO |
Dr. Roland Rutschmann |
Management board |
Patrick Ramsauer |
Supervisory board |
Dr. Marian Borovsky, Dr. Roland Rutschmann, Günter Graubach, Dr. Silvio Inderbitzin |
Company data
Name: |
Curatis Holding AG |
Address: |
Weierweg 7,Liestal |
Phone: |
+41 61 927 8777 |
Fax: |
+41 61 927 8775 |
E-mail: |
-
|
Internet: |
https://curatis.com/ |
Industry: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Sub sector: |
Pharmaceuticals |
End of financial year: |
12-31 |
Free Float: |
- |
IPO date: |
2024-04-26 |